Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 432, Issue C, Pages 66-75Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2016.05.008
Keywords
FGF23; Fibroblast growth factor-23; Klotho; Bone; Kidney; Parathyroid gland
Categories
Funding
- Austrian Science Fund [FWF 24186-B21]
- Austrian Science Fund (FWF) [P 24186] Funding Source: researchfish
- Austrian Science Fund (FWF) [P24186] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Fibroblast growth factor-23 (FGF23) is a bone-derived hormone known to suppress phosphate reabsorption and vitamin D hormone production in the kidney. Klotho was originally discovered as an anti aging factor, but the functional role of Klotho is still a controversial issue. Three major functions have been proposed, a hormonal function of soluble Klotho, an enzymatic function as glycosidase, and the function as an obligatory co-receptor for FGF23 signaling. The purpose of this review is to highlight the recent advances in the area of FGF23 and Klotho signaling in the kidney, in the parathyroid gland, in the cardiovascular system, in bone, and in the central nervous system. During recent years, major new functions of FGF23 and Klotho have been discovered in these organ systems. Based on these novel findings, FGF23 has emerged as a pleiotropic endocrine and auto-/paracrine factor influencing not only mineral metabolism but also cardiovascular function. (C) 2016 The Author. Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available